Opportunity amid volatility, uncertainty, complexity and ambiguity (VUCA) in the changing MSL value proposition

Even before the COVID-19 pandemic, the structure and content of interactions between MSLs and KOLs/HCPs was shifting, with MSLs increasingly seen as trusted partners in scientific exchange and KOLs/HCPs increasingly open to technology-based communications. Of course, the pandemic has accelerated this change, shifting the mechanics of communication and collaboration and throwing into focus the definition of “value.” This podcast presents the expertise of leaders from pharmaceutical organizations Pfizer and Nektar, as well as Larvol, focusing on how MSLs bring value to HCPs and KOLs during the time of pandemic.Speakers: ·      Tim Hylan, VP, Internal Medicine Field Medical Director Group at Pfizer·      Sue Currie, VP, Head of Medical Affairs at Nektar Therapeutics·      Bruno Larvol, Founder and CEO at Larvol